(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 41.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Ocular Therapeutix's revenue in 2024 is $58,443,000.On average, 3 Wall Street analysts forecast OCUL's revenue for 2024 to be $10,563,843,854, with the lowest OCUL revenue forecast at $10,032,352,133, and the highest OCUL revenue forecast at $11,340,273,596. On average, 2 Wall Street analysts forecast OCUL's revenue for 2025 to be $14,485,230,205, with the lowest OCUL revenue forecast at $11,702,924,547, and the highest OCUL revenue forecast at $17,267,535,863.
In 2026, OCUL is forecast to generate $26,107,152,798 in revenue, with the lowest revenue forecast at $13,214,465,601 and the highest revenue forecast at $38,999,839,994.